Company Announcement

Copenhagen, Denmark; February 17, 2016 – Genmab A/S (OMX: GEN) announced today
its Annual Report for 2015. Below is a summary of business progress and
financial performance for the year, and financial outlook for 2016 from the
report. The full report is attached as a PDF file and can be found on the
investor section of the company’s website, www.genmab.com.

2015 ACHIEVEMENTS
Business Progress

Maximize daratumumab clinical progress

-- Phase II multiple myeloma (MM) monotherapy data, and, if favorable, discuss
regulatory next steps with health authorities - Achieved
-- Start multiple new MM trials - Achieved
-- Start non-MM clinical trial - Achieved

Optimize ofatumumab value

-- File for an additional indication - Achieved
-- Phase III relapsed chronic lymphocytic leukemia (CLL) data - Achieved
-- Start Phase III subcutaneous autoimmune trials – Moved to 2016

Strengthen differentiated product pipeline

-- Phase I tisotumab vedotin (HuMax-TF-ADC) data - Achieved
-- Progress HuMax-AXL-ADC - Achieved
-- Progress pre-clinical DuoBody & HexaBody projects - Achieved

Broaden partnership portfolio with next generation technologies

-- Expand DuoBody & HexaBody collaborations - Achieved
-- Progress partnered programs - Achieved
-- New Investigational New Drug (IND) filings - Achieved

Disciplined financial management

-- Maintain cost base while selectively investing to advance pipeline -
Achieved

Financial Performance

-- Revenue increased by DKK
283
million, from DKK 850 million in 2014 to DKK 1,133 million in 2015, mainly
driven by higher revenue related to our daratumumab and DuoBody
collaborations with Janssen.
-- Operating expenses were reduced from DKK 585 million in 2014 to DKK 579
million in 2015.
-- Operating income improved by DKK 465 million, from DKK 265 million in 2014
to DKK 730 million in 2015.
-- 2015 year end cash position of DKK 3,493 million, compared to DKK 2,661
million as of December 31, 2014.

2016 OUTLOOK

MDKK 2016 Guidance 2015 Actual Result
----------------------------------------------------------------
Revenue 825 – 875 1,133
----------------------------------------------------------------
Operating expenses (775) – (825) (579)
----------------------------------------------------------------
Reversal of GSK liability - 176
----------------------------------------------------------------
Operating income 25 – 75 730
----------------------------------------------------------------
Cash position at end of year* 3,300 – 3,400 3,493
----------------------------------------------------------------
*Cash, cash equivalents, and marketable securities
-----------------------------------------------------------------

Conference Call
Genmab will hold a conference call in English to discuss the results for the
full year 2015 today, Wednesday, February 17, at 6.00 pm CET, 5.00 pm GMT or
noon EST. The dial in numbers are:

+1 646 254 3367 (US participants) and ask for the Genmab conference call
+44 20 3427 1911 (international participants) and ask for the Genmab conference
call

A live and archived webcast of the call and relevant slides will be available
at www.genmab.com.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin’s lymphoma.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody® platform which creates effector function enhanced antibodies.
The company intends to leverage these technologies to create opportunities for
full or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: [email protected]

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX™ is a trademark of Janssen Biotech, Inc.

Company Announcement no. 03
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

03_Genmab_AR15_170216.pdf